Immunome, Inc. (IMNM)
After hours:
| Previous Close | 14.26 |
| Open | 14.28 |
| Bid | 13.68 x 200 |
| Ask | 13.75 x 200 |
| Day's Range | 13.70 - 14.28 |
| 52 Week Range | 4.44 - 30.96 |
| Volume | |
| Avg. Volume | 803,233 |
| Market Cap | 819.601M |
| Beta (5Y Monthly) | 1.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.38 |
| Earnings Date | May 03, 2024 - May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.33 |
ZacksAnalysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireImmunome Appoints Sandra M. Swain to Board of Directors
BOTHELL, Wash., April 25, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors. Dr. Swain has over 30 years of oncology clinical research experience and has served on both public company and non-profit boards.
Business WireImmunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash., April 05, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP). Jack Higgins, PhD, Chief Scientific Officer at Immunome, will present the data in a poster at the American Association for Cancer Research (AACR) Annual Meetin
